• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacogenetics and the immunogenicity of protein therapeutics.

作者信息

Yanover Chen, Jain Nisha, Pierce Glenn, Howard Tom E, Sauna Zuben E

出版信息

Nat Biotechnol. 2011 Oct 13;29(10):870-3. doi: 10.1038/nbt.2002.

DOI:10.1038/nbt.2002
PMID:21997623
Abstract
摘要

相似文献

1
Pharmacogenetics and the immunogenicity of protein therapeutics.药物遗传学与蛋白质治疗药物的免疫原性
Nat Biotechnol. 2011 Oct 13;29(10):870-3. doi: 10.1038/nbt.2002.
2
CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.针对野生型凝血因子VIII的CD4 + T细胞克隆：轻度/中度A型血友病中抑制剂形成发生率较高的分子机制。
Blood. 2003 Feb 15;101(4):1351-8. doi: 10.1182/blood-2002-05-1369. Epub 2002 Oct 17.
3
[Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].[血友病抑制剂的研发及血友病患者的预防与管理策略]
Zhonghua Er Ke Za Zhi. 2013 Aug;51(8):631-4.
4
In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.基于计算机计算的 FVIII 衍生肽与 HLA Ⅱ类等位基因的亲和力可预测 F8 基因突变的血友病 A 患者产生抑制剂的情况。
Haemophilia. 2014 Mar;20(2):176-84. doi: 10.1111/hae.12276. Epub 2013 Oct 14.
5
The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics.内含子22倒位的F8基因座允许因子VIII合成：低抑制剂风险的解释及药物基因组学的作用。
Blood. 2015 Jan 8;125(2):223-8. doi: 10.1182/blood-2013-12-530113. Epub 2014 Nov 18.
6
Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.第二代重组凝血因子VIII与抑制物风险：解读RODIN研究结果及其对甲型血友病患者的影响
Haemophilia. 2014 Mar;20(2):e171-4. doi: 10.1111/hae.12342. Epub 2013 Dec 26.
7
Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted.
Blood. 2007 Oct 15;110(8):3084; author reply 3085. doi: 10.1182/blood-2007-06-095166.
8
Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.缺乏证据表明从血浆源性因子VIII转换为重组因子VIII的患者中抑制剂发生率增加。
Haemophilia. 2001 Jul;7(4):346-8. doi: 10.1046/j.1365-2516.2001.00515.x.
9
The evolution of recombinant factor replacement for hemophilia.血友病重组因子替代疗法的演变
Transfus Apher Sci. 2019 Oct;58(5):596-600. doi: 10.1016/j.transci.2019.08.010. Epub 2019 Aug 9.
10
World registry on factor VIII inhibitor patients: why?
Semin Hematol. 1993 Apr;30(2 Suppl 1):7-9.

引用本文的文献

1
A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.对多效性免疫介导疾病基因的扫描确定了甲型血友病中基线FVIII抑制物状态的新决定因素。
Genes Immun. 2025 Apr 22. doi: 10.1038/s41435-025-00325-7.
2
Suborgan Level Quantitation of Proteins in Tissues Delivered by Polymeric Nanocarriers.聚合物纳米载体递送的组织中蛋白质的亚器官水平定量。
ACS Nano. 2024 Jul 2;18(26):16808-16818. doi: 10.1021/acsnano.4c02344. Epub 2024 Jun 13.
3
A Scan of Pleiotropic Immune Mediated Disease Genes Identifies Novel Determinants of Baseline FVIII Inhibitor Status in Hemophilia-A.

本文引用的文献

1
Prediction of immunogenicity of therapeutic proteins: validity of computational tools.治疗性蛋白免疫原性预测：计算工具的有效性。
BioDrugs. 2010 Feb 1;24(1):1-8. doi: 10.2165/11318560-000000000-00000.
2
Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.在抗凝血因子VIII免疫反应不同阶段分离出的人类T细胞克隆谱系，包括辅助性T细胞17/辅助性T细胞1。
Blood. 2009 Aug 13;114(7):1423-8. doi: 10.1182/blood-2009-01-200725. Epub 2009 Jun 23.
3
Inhibitors of factor VIII in black patients with hemophilia.
对多效性免疫介导疾病基因的扫描揭示了血友病A中基线FVIII抑制剂状态的新决定因素。
Res Sq. 2023 Oct 18:rs.3.rs-3371095. doi: 10.21203/rs.3.rs-3371095/v1.
4
A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII.一种用于识别与产生针对凝血因子VIII的中和抗药物抗体风险相关变量的机器学习方法。
Heliyon. 2023 May 23;9(6):e16331. doi: 10.1016/j.heliyon.2023.e16331. eCollection 2023 Jun.
5
Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.在受到界面扩张压力时，用 PS20 和 PS80 配制的 IgG1 mAbs 中蛋白颗粒形成的比较。
AAPS PharmSciTech. 2023 Apr 20;24(5):104. doi: 10.1208/s12249-023-02561-4.
6
Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.HLA-DRB1 等位基因变异与接受阿特珠单抗治疗的癌症患者产生体外中和性抗药物抗体有关。
Clin Transl Sci. 2022 Jun;15(6):1393-1399. doi: 10.1111/cts.13264. Epub 2022 Apr 8.
7
Harnessing cyclotides to design and develop novel peptide GPCR ligands.利用环肽设计和开发新型肽类G蛋白偶联受体配体。
RSC Chem Biol. 2020 Jul 22;1(4):177-191. doi: 10.1039/d0cb00062k. eCollection 2020 Oct 1.
8
HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset.血友病A中的HLA变异与抑制剂的产生：一项使用ATHN数据集的回顾性病例对照研究
Front Med (Lausanne). 2021 May 7;8:663396. doi: 10.3389/fmed.2021.663396. eCollection 2021.
9
Immunogenicity Risk Profile of Nanobodies.纳米抗体的免疫原性风险概况。
Front Immunol. 2021 Mar 9;12:632687. doi: 10.3389/fimmu.2021.632687. eCollection 2021.
10
De novo design of functional zwitterionic biomimetic material for immunomodulation.用于免疫调节的功能性两性离子仿生材料的从头设计。
Sci Adv. 2020 May 29;6(22):eaba0754. doi: 10.1126/sciadv.aba0754. eCollection 2020 May.
黑人血友病患者中凝血因子VIII抑制剂
N Engl J Med. 2009 Apr 16;360(16):1618-27. doi: 10.1056/NEJMoa075760.
4
Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.凝血因子VIII抑制剂：危险因素及预防和免疫调节方法
Clin Rev Allergy Immunol. 2009 Oct;37(2):114-24. doi: 10.1007/s12016-009-8122-5.
5
Quality by design for biopharmaceuticals.生物制药的质量源于设计
Nat Biotechnol. 2009 Jan;27(1):26-34. doi: 10.1038/nbt0109-26.
6
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.治疗性酶的中和抗体：检测、预防及治疗方面的考量
Nat Biotechnol. 2008 Aug;26(8):901-8. doi: 10.1038/nbt.1484.
7
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach.MHC II类肽结合预测的系统评估及一种共识方法的评价
PLoS Comput Biol. 2008 Apr 4;4(4):e1000048. doi: 10.1371/journal.pcbi.1000048.
8
A second generation human haplotype map of over 3.1 million SNPs.一张包含超过310万个单核苷酸多态性的第二代人类单倍型图谱。
Nature. 2007 Oct 18;449(7164):851-61. doi: 10.1038/nature06258.
9
Prediction of immunogenicity for therapeutic proteins: state of the art.治疗性蛋白质免疫原性的预测：现状
Curr Opin Drug Discov Devel. 2007 May;10(3):332-40.
10
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs.一种基于风险的生物分析策略，用于评估针对生物药物的抗体免疫反应。
Nat Biotechnol. 2007 May;25(5):555-61. doi: 10.1038/nbt1303.